Brege Laura — SEC insider filings
SEC reporting owner CIK 1365619. 33 insider filings on record with FilingPulse; latest filed 2026-11-17.
Transaction summary — filings shown
Covers all 33 filings on record, filed 2020-11-17 to 2026-11-17. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 1,000 shares, $12,810 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 10 legs across 8 filings — 82,213 shares, $4,353,873 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 74.
- Largest priced transaction: sale of 15,509 shares @ $74.34 ($1,152,939) in Mirum Pharmaceuticals, Inc., filed 2025-09-12.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Mirum Pharmaceuticals, Inc. (MIRM) | Director | 8 | — | 4 legs · 31,167 sh · $2,599,524 | 15 |
| Pacira BioSciences, Inc. (PCRX) | Director | 11 | 1 leg · 1,000 sh · $12,810 | 3 legs · 19,600 sh · $1,099,684 | 28 |
| ACADIA PHARMACEUTICALS INC (ACAD) | Director | 9 | — | 3 legs · 31,446 sh · $654,665 | 26 |
| Edgewise Therapeutics, Inc. (EWTX) | Director | 5 | — | — | 5 |
Insider filings — Brege Laura
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-17 | 4 | Pacira BioSciences, Inc. (PCRX) | Code (U): 23,715 @ $36.50 · Disposition to issuer (D): 6,405 @ $36.50 · Disposition to issuer (D): 2,975 (derivative) · Disposition to issuer (D): 4,693 (derivative) · Disposition to issuer (D): 8,437 (derivative) · Disposition to issuer (D): 8,027 (derivative) · +6 more | EDGAR |
| 2026-11-13 | 4 | Mirum Pharmaceuticals, Inc. (MIRM) | Option exercise (M): 14,167 @ $16.71 · Sale (S): 10,907 @ $94.05 · Sale (S): 3,260 @ $94.74 · Option exercise (M): 14,167 (derivative) @ $0 | EDGAR |
| 2026-06-17 | 4 | Edgewise Therapeutics, Inc. (EWTX) | Grant/award (A): 16,377 (derivative) @ $0 | EDGAR |
| 2026-06-17 | 4 | Mirum Pharmaceuticals, Inc. (MIRM) | Grant/award (A): 3,772 (derivative) @ $0 · Grant/award (A): 1,980 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Pacira BioSciences, Inc. (PCRX) | Grant/award (A): 6,405 @ $0 · Grant/award (A): 10,891 (derivative) @ $0 | EDGAR |
| 2026-06-01 | 4 | ACADIA PHARMACEUTICALS INC (ACAD) | Option exercise (M): 8,107 · Option exercise (M): 8,107 (derivative) @ $0 · Grant/award (A): 16,004 (derivative) @ $0 · Grant/award (A): 9,311 (derivative) @ $0 | EDGAR |
| 2025-09-12 | 4 | Mirum Pharmaceuticals, Inc. (MIRM) | Option exercise (M): 17,000 @ $15 · Sale (S): 15,509 @ $74.34 · Sale (S): 1,491 @ $75.07 · Option exercise (M): 17,000 (derivative) @ $0 | EDGAR |
| 2025-06-18 | 4 | Edgewise Therapeutics, Inc. (EWTX) | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Pacira BioSciences, Inc. (PCRX) | Grant/award (A): 6,163 @ $0 · Grant/award (A): 11,279 (derivative) @ $0 | EDGAR |
| 2025-06-05 | 4 | ACADIA PHARMACEUTICALS INC (ACAD) | Sale (S): 14,446 @ $21.78 | EDGAR |
| 2025-06-02 | 4 | ACADIA PHARMACEUTICALS INC (ACAD) | Option exercise (M): 9,387 · Option exercise (M): 9,387 (derivative) @ $0 · Grant/award (A): 13,793 (derivative) @ $0 · Grant/award (A): 8,107 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | Mirum Pharmaceuticals, Inc. (MIRM) | Option exercise (M): 5,703 · Option exercise (M): 5,703 (derivative) @ $0 · Grant/award (A): 6,268 (derivative) @ $0 · Grant/award (A): 3,977 (derivative) @ $0 | EDGAR |
| 2024-08-19 | 4 | Pacira BioSciences, Inc. (PCRX) | Purchase (P): 1,000 @ $12.81 | EDGAR |
| 2024-06-13 | 4 | Pacira BioSciences, Inc. (PCRX) | Grant/award (A): 5,230 @ $0 · Grant/award (A): 12,179 (derivative) @ $0 | EDGAR |
| 2024-06-12 | 4 | Edgewise Therapeutics, Inc. (EWTX) | Grant/award (A): 20,594 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | Mirum Pharmaceuticals, Inc. (MIRM) | Grant/award (A): 8,779 (derivative) @ $0 · Grant/award (A): 5,703 (derivative) @ $0 | EDGAR |
| 2024-05-31 | 4 | ACADIA PHARMACEUTICALS INC (ACAD) | Option exercise (M): 6,652 · Option exercise (M): 6,652 (derivative) @ $0 · Grant/award (A): 15,959 (derivative) @ $0 · Grant/award (A): 9,387 (derivative) @ $0 | EDGAR |
| 2023-06-16 | 4 | Pacira BioSciences, Inc. (PCRX) | Grant/award (A): 1,775 @ $0 · Grant/award (A): 12,925 (derivative) @ $0 | EDGAR |
| 2023-06-14 | 4 | ACADIA PHARMACEUTICALS INC (ACAD) | Sale (S): 4,500 @ $24.87 | EDGAR |
| 2023-06-14 | 4 | Mirum Pharmaceuticals, Inc. (MIRM) | Grant/award (A): 17,000 (derivative) @ $0 | EDGAR |
| 2023-06-14 | 4 | Edgewise Therapeutics, Inc. (EWTX) | Grant/award (A): 22,123 (derivative) @ $0 | EDGAR |
| 2023-06-07 | 4 | Pacira BioSciences, Inc. (PCRX) | Sale (S): 600 @ $38.74 | EDGAR |
| 2023-06-05 | 4 | ACADIA PHARMACEUTICALS INC (ACAD) | Option exercise (M): 3,059 · Option exercise (M): 6,391 · Option exercise (M): 8,552 · Option exercise (M): 3,059 (derivative) @ $0 · Option exercise (M): 6,391 (derivative) @ $0 · Option exercise (M): 8,552 (derivative) @ $0 · +2 more | EDGAR |
| 2023-04-05 | 4 | Pacira BioSciences, Inc. (PCRX) | Option exercise (M): 7,000 @ $29.90 · Sale (S): 7,000 @ $40.72 · Option exercise (M): 7,000 (derivative) @ $0 | EDGAR |
| 2023-01-17 | 4 | ACADIA PHARMACEUTICALS INC (ACAD) | Option exercise (M): 12,500 @ $17.01 · Sale (S): 12,500 @ $18.25 · Option exercise (M): 12,500 (derivative) @ $0 | EDGAR |
| 2022-06-28 | 4 | Edgewise Therapeutics, Inc. (EWTX) | Grant/award (A): 42,087 (derivative) @ $0 | EDGAR |
| 2022-06-09 | 4 | ACADIA PHARMACEUTICALS INC (ACAD) | Grant/award (A): 14,368 (derivative) @ $0 · Grant/award (A): 8,552 (derivative) @ $0 | EDGAR |
| 2022-06-08 | 4 | Pacira BioSciences, Inc. (PCRX) | Grant/award (A): 1,160 @ $0 · Grant/award (A): 8,225 (derivative) @ $0 | EDGAR |
| 2022-06-06 | 4 | Mirum Pharmaceuticals, Inc. (MIRM) | Grant/award (A): 17,000 (derivative) @ $0 | EDGAR |
| 2021-06-24 | 4 | ACADIA PHARMACEUTICALS INC (ACAD) | Grant/award (A): 11,637 (derivative) @ $0 · Grant/award (A): 6,391 (derivative) @ $0 | EDGAR |
| 2021-06-11 | 4 | Pacira BioSciences, Inc. (PCRX) | Grant/award (A): 1,066 @ $0 · Grant/award (A): 7,626 (derivative) @ $0 | EDGAR |
| 2021-06-08 | 4 | Mirum Pharmaceuticals, Inc. (MIRM) | Grant/award (A): 17,000 (derivative) @ $0 | EDGAR |
| 2020-11-17 | 4 | Pacira BioSciences, Inc. (PCRX) | Option exercise (M): 12,000 @ $13.98 · Sale (S): 12,000 @ $65.95 · Option exercise (M): 12,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-10-05 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1365619 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs